A Randomized, Open Label, Multiple Dose, Parallel Group Study to Assess the Safety and Pharmacokinetic Comparability of Two VAY736 Drug Products in Patients With Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Ianalumab (Primary) ; Ianalumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 29 Oct 2019 Planned End Date changed from 14 Dec 2021 to 15 Feb 2022.
- 29 Oct 2019 Planned primary completion date changed from 14 Dec 2021 to 15 Feb 2022.
- 18 Jul 2019 Planned End Date changed from 31 Aug 2021 to 14 Dec 2021.